Background: Mycobacterium tuberculosis DNA topoisomerase I is an attractive target for discovery of novel TB drugs that act by enhancing the accumulation of the topoisomerase-DNA cleavage product. It shares a common transesterification domain with other type IA DNA topoisomerases. There is, however, no homology between the C-terminal DNA binding domains of Escherichia coli and M. tuberculosis DNA topoisomerase I proteins.
Background
DNA topoisomerases are ubiquitous enzymes involved in the regulation of DNA supercoiling and overcoming topological barriers during replication, transcription, recombination and repair. In bacteria, the major classes of topoisomerases, type IA and type IIA, modify DNA topology by transiently cleaving and rejoining one or two strands of DNA respectively [1, 2] . Both of these classes form a 5'-phosphotyrosyl enzyme-DNA linkage during the catalytic cycle of DNA cleavage and religation [1] . Topoisomerases are attractive targets for development of new anti-infectives [3] . Bacterial DNA gyrase and topoisomerase IV from the type IIA class are targets of antibiotics such as quinolones and fluoroquinolones. These antibiotics exhibit their bactericidal properties by trapping the covalent protein-DNA complexes formed by DNA gyrase or topoisomerase IV [4, 5] . Although fluoroquinolones are effective against a broad spectrum of bacteria, alarming increase in fluoroquinolone-resistant pathogens warrants the need to develop novel drugs against new cellular targets.
Bacterial topoisomerase I, responsible for relaxing negatively supercoiled DNA, is the most common type IA topoisomerase present in almost all bacteria [6, 7] . Escherichia coli topoisomerase I (EcTOP) is the well studied prototype for type IA topoisomerase [8] . EcTOP relaxes negatively supercoiled DNA through a magnesium-dependent, ATP-independent catalytic mechanism. No specific inhibitor for bacterial topoisomerase I, effective at a relevant clinical and physiological concentration, has been identified. Bacterial topoisomerase I, by virtue of its presence in nearly all bacterial genomes, and in view of its association with DNA during the vulnerable stage of cleavage-religation, could be utilized as a target for novel antimicrobials [3] . This strategy could be useful in developing drugs to treat highly fatal bacterial diseases like tuberculosis [9] . The fact that approximately one-third of the world's population is affected by tuberculosis indicates the need to develop effective drugs against this disease [10] . Also, since multiple drug resistance is common in Mycobacterium tuberculosis, it would be significant if a novel antibiotic targeting M. tuberculosis DNA topoisomerase I can be developed [9] .
A logical first step towards finding inhibitors selective to M. tuberculosis topoisomerase I is to characterize the DNA modification ability of this enzyme. In this study, we describe a new expression and purification protocol for recombinant M. tuberculosis topoisomerase I capable of producing milligrams of pure protein. We also report the first detailed characterization of this enzyme with respect to its DNA cleavage sites and relaxation activity under different assay conditions.
Results

Expression and purification of M. tuberculosis topoisomerase I
Genome sequencing of M. tuberculosis H37Rv strain has revealed the presence of topA gene Rv3646c which encodes a DNA topoisomerase I (MtTOP) comprising of 934 amino acids with an estimated molecular weight of 102.3 kDa [11] . Previously, Yang et al [12] have cloned and purified DNA topoisomerase I from M. tuberculosis Erdman strain in E. coli BL21 (DE3). Our efforts to express and purify recombinant MtTOP in E. coli BL21 (DE3) similarly by induction of the T7 promoter were frustrated by the insolubility of the expressed protein. Difficulties have also been encountered by other researchers [13] while trying to use recombinant DNA topoisomerase I gene present in genomic libraries of M. tuberculosis and Mycobacterium smegmatis to complement the temperature dependent deficiency of topoisomerase I (topA) function in E. coli strain AS17 [14] . Difference in codon usage was surmised to be one of the possible reasons behind this result [13] . We overcame these difficulties by expressing MtTOP from a recombinant plasmid pLIC-MTOP in an E. coli Arctic express (DE3)RP strain (Stratgene) at low temperatures (12°C). The Arctic express (DE3)RP strain contained a chromosomally integrated T7 RNA polymerase which was expressed from the lacUV5 promoter. Induction of T7 RNA polymerase protein synthesis with IPTG resulted in the expression of the T7 promoter-driven recombinant protein. In addition, the Arctic express (DE3)RP strain expressed cold chaperonin proteins (Cpn10 and CPn60) and extra copies of tRNAs (recognizing arginine and proline codons) that facilitated the expression of recombinant proteins by overcoming issues of protein solubility and codon bias respectively.
Recombinant MtTOP was soluble and initially expressed as a hexa-histidine fusion protein only in the presence of IPTG ( Figure 1 ). Purification of the fusion protein was achieved using nickel affinity chromatography. Subsequent SDS-PAGE analysis (Figure 2A ) showed the predominant presence of only the fusion protein with the expected molecular weight. The hexa-histidine fusion tag was cleaved off by TEV protease treatment and MtTOP of high purity was eluted by increasing the potassium chloride gradient from a single-stranded DNA cellulose column ( Figure 2B ) [15] . The eluted fractions were pooled and dialyzed into storage buffer. Approximately 12 milligrams of purified protein was obtained from 7 L of bacterial culture in LB medium. For a more detailed analysis of the relaxation activity of the purified enzymes, a time course assay with 50 ng each of MtTOP and EcTOP was performed (Figure 4 ). At the early time points, the rate of removal of the negative supercoils by the two enzymes was similar. However, as the plasmid DNA substrate became partially relaxed, the relaxation activity of MtTOP was less efficient than EcTOP in removing the residual negative supercoils.
Expression of recombinant MtTOP in E. coli Arctic express (DE3)RP strain
It has been a well known fact that Mg 2+ ions are required for the relaxation activity of bacterial type IA topoisomerases, including E. coli topoisomerase I [17, 18] . We compared the Mg 2+ dependence of the relaxation activity of EcTOP and MtTOP using two different enzyme concentrations (50 ng or 1 unit in a 20-μl assay) and a range of Mg 2+ levels ( Figure 5 ). At a lower enzyme concentration (50 ng), relaxation by EcTOP had a optimal range of Mg 2+ concentrations between 2.5 to 7.5 mM while the optimal range of Mg 2+ concentrations for MtTOP was slightly higher (5-12.5 mM) ( Figure 5B ). Similar optimal levels of Mg 2+ were found for the relaxation activities of both the EcTOP and MtTOP at higher enzyme concentrations equivalent to one unit of enzyme activity, with no relaxation observed in the absence of Mg 2+ ( Figure 5A ). The optimal Mg 2+ concentrations found here for MtTOP are higher than the 1 mM concentration determined in previous work [12] . In other studies involving the characterization of the topoisomerase I from M. smegmatis, the optimal Mg 2+ concentration for relaxation activity was found to be about 5 mM [19] .
Mapping of DNA cleavage sites using single-stranded DNA substrates
Although the majority of topoisomerases do not have specific sequence requirements for cleavage sites, many of them show at least a certain degree of non -randomness in cleavage site recognition [6, 20] . For example, EcTOP and Micrococcal luteus topoisomerase I cleave the sequence SDS PAGE at different stages of MtTOP purification CXXX↓ (↓ represents the cleavage site) more preferentially than others [21] . Archeal and bacterial reverse gyrases, which are type IA topoisomerases, also have limited sequence requirements with only the preference of a cytosine or requirement of at least a pyrimidine at the -4 position of the cleavage site [22] [23] [24] . Previous studies elucidating the sequence specificity of topoisomerase I from M. smegmatis reported a strong topoisomerase I site (STS), wherein the enzyme recognizes and cleaves the sequence CG/TCT↓T [25, 26] . We utilized different singlestranded 5'-32 P labeled DNA substrates ranging from 200-550 bases in length generated from either an E. coli plasmid or M. tuberculosis genomic DNA to characterize the MtTOP preferred cleavage sites. Results indicate that the DNA cleavage selectivity of MtTOP is very similar to that of EcTOP ( Figure 6A , Table 1 ). The two enzymes share many cleavage sites on DNA derived either from E. coli or M. tuberculosis, but some cleavage sites were preferred by only one of these two enzymes ( Figure 6B , Table  1 ). All of the cleavage sites for both enzymes were found to have a cytosine at the -4 position (CXXX↓) as previously shown for many bacterial topoisomerase I enzymes [21, 27] . There was no specific cleavage sequence recognition for MtTOP as reported for M. smegmatis topoisomerase I.
Discussion
Tuberculosis (TB) is the second leading cause of adult deaths due to infectious diseases world-wide, second only to HIV. The surge in multi-drug resistant M. tuberculosis makes it crucial to identify novel targets for development of new TB treatment. M. tuberculosis topoisomerase I could be one such novel target since there is only one type IA topoisomerase found in M. tuberculosis. A recent genome wide transposon mutagenesis experiment has postulated and categorised M. tuberculosis topA gene as essential [28] . It is also likely to be essential because every bacterium has at least one type IA topoisomerase activity. MtTOP is therefore an attractive target for drugs which would interfere with its relaxation activity (catalytic inhibitors). Moreover, besides inhibiting the overall relaxation activity of MtTOP, a more potent bactericidal effect could be achieved by drugs (catalytic poisons) that enhance the accumulation of covalent complexes on DNA, similar to the bactericidal mechanism of fluoroquinolones on type IIA bacterial topoisomerases. To aide such drug development efforts, it is important to have MtTOP protein in high purity and quantity. Here we report that by utilizing the E. coli Arctic express RP(DE3) strain, we took advan-tage of the higher GC rich codon usage efficiency and low temperature chaperone in this strain to obtain soluble MtTOP in high yield (12 mg from 7 L of bacterial culture). This enables future development of high through-put assays for inhibitors targeting MtTOP.
Time course of DNA relaxation
The DNA cleavage activity of MtTOP has not been characterized previously and there is a also a need for more detailed analysis of its DNA relaxation activity than in the early study of the enzyme [12] . Careful comparison with E. coli topoisomerase I (EcTOP) showed that the two enzymes had similar efficiency initially in relaxing the negatively supercoiled plasmid DNA isolated from E. coli. 
Sequences cleaved by MtTOP alone
Sequences cleaved by EcTOP alone
a Sequences are numbered from -6 to 6 (5' to 3'). Topoisomerase I mediated cleavage occurs between -1 and 1. b Among sequences cleaved by both EcTOP and MtTOP, sequences showing at least one-fold higher cleavage intensity towards EcTOP or MtTOP than the other enzyme are grouped as EcTOP or MtTOP preferred sequences respectively However, as the substrate plasmid DNA became partially relaxed, MtTOP was slower than EcTOP in removing the residual negative supercoils. This could be due to the different C-terminal domain found in the enzymes. The Cterminal domain found in EcTOP has been proposed to be important for substrate binding and coordination of strand passage during the relaxation cycle [29, 30] . The Cterminal domain of MtTOP has no homology to the C-terminal domain in EcTOP, so it may function differently during the catalytic cycle. The N-terminal two-thirds, the transesterification domains of EcTOP and MtTOP have high degree of homology (41.9% identical).
Analysis of cleavage sites on both E. coli and M. tuberculosis derived DNA substrate showed that the cleavage site preferences are quite similar with a C in the -4 position as have been observed for several bacterial topoisomerase I as well as archeal and bacterial reverse gyrase enzymes. It is somewhat surprising that the cleavage site preference of MtTOP is not the same as that reported for M. smegmatis topoisomerase I (CG/TCT↓T). It is possible that this is due to the different experimental protocols used in analysis of the cleavage sites [25, 26] . Besides M. smegmatis topoisomerase I, there are other examples of type IA topoisomerases that have cleavage site preferences different from that of EcTOP. These include CTT↓ for E. coli topoisomerase III [31] , CANNN↓ for human topoisomerase III [32] , ANN↓ for yeast topoisomerase III [33] . It remains unclear which part of the type IA enzyme structure determines the cleavage site selectivity. The specific sequence information for DNA cleavage by MtTOP should be useful in design of oligonucleotide substrates for DNA cleavage assays.
Conclusion
A new procedure for expression and purification of recombinant MtTOP protein in high yield has been described. The enzyme is as efficient as EcTOP in initial removal of negative supercoils from plasmid DNA, but is less efficient than EcTOP in removing the remaining negative supercoils. The preferred DNA cleavage sites of MtTOP have limited sequence specificity but contain a C nucleotide in the -4 position, similar to most bacterial topoisomerase I and archeal reverse gyrase cleavage sites characterized previously.
Methods
MtTOP expression and purification
MtTOP was expressed from a recombinant plasmid pLIC-MTOP in E.coli Arctic express (DE3)RP strain (Stratagene). MtTOP coding sequence was amplified from the genomic DNA of M. tuberculosis H37RV strain with suitable primers (LIC-Mtop5'-TACTTCCAATCCAATGCAGCTGACCCGA A AACG and LIC-Mtop3'-TTATCCACTTCCAATGTTATT-AGTCGCGCTTGGCTGC) using PfuUltra II Fusion HS DNA polymerase (Stratagene) and cloned into a vector pLIC-HK [34] through a ligation independent cloning procedure [35] . Cloning of MtTOP coding sequence into this vector containing a T7 promoter allowed T7 RNA polymerase dependent expression of MtTOP along with a tobacco etch virus (TEV) protease-cleavable N-terminal hexahistidine tag [34] . The resulting pLIC-MTOP plasmid, capable of expressing recombinant MtTOP was first isolated in E. coli NEB Turbo competent cells (New England Biolabs) and then transformed into Arctic express (DE3)RP cells after sequence confirmation. Expression of MtTOP in transformed Arctic express (DE3)RP cells was induced by 1 mM IPTG at 12°C according to the manufacturer's (Stratagene) protocol. After 24 h of induction, the cells were collected and subjected to freeze-thaw lysis [15] in lysis buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, 1 mg/ml Lysozyme, pH 8.0). The recombinant protein in the soluble lysate was allowed to bind to Ni-NTA agarose (Qiagen) and packed into a column. After washing the column overnight with wash buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 20 mM imidazole, pH 8.0), the topoisomerase protein was eluted with an elution buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 250 mM Imidazole, pH 8.0) containing higher concentrations of imidazole. Eluted MtTOP was cleaved with TEV protease to remove the N-terminal hexa-histidine tag and purified by passing through a single-stranded DNA cellulose column as described [15] .
DNA Relaxation Activity assays
To assay for one unit of relaxation activity, EcTOP [16] and MtTOP enzymes of the same concentrations were diluted serially, ranging from 500-1 ng and assayed for DNA relaxation activity in a standard reaction volume of 20 μl with 10 mM Tris-HCl (pH 8.0), 50 mM NaCl, 0.1 mg/ml gelatin, 6 mM MgCl 2 and 0.5 μg of supercoiled pBAD/thio plasmid DNA (purified by CsCl gradient centrifugation). After incubation at 37°C for 30 min, the reactions were stopped by adding 5 ul of 50 mM EDTA, 50% glycerol and 0.5%(v/v) bromophenol blue. The DNA was electrophoresed in a 1.0% (w/v) agarose gel with TAE buffer (40 mM Tris-acetate, pH 8.1, 2 mM EDTA). The gel was stained with ethidium bromide and photographed over UV light. One unit of enzyme was defined as the least quantity of the enzyme required for complete relaxation of negatively supercoiled DNA under the given reaction conditions.
Mg 2+ dependence of EcTOP and MtTOP to relax negatively supercoiled DNA was compared with either 50 ng or one unit of enzyme (100 ng of EcTOP, 500 ng of MtTOP) under varying concentrations of MgCl 2 ranging from 0-20 mM over a time period of 30 min at 37°C with similar reaction conditions as described above. Also, a low concentration (50 ng) of EcTOP and MtTOP under standard conditions (6 mM MgCl 2 ) as described earlier was used to compare the ability of the respective enzymes to relax negatively supercoiled DNA at various time points of 0, 10, 20, 30, 45, 60, 75, 90, 120 and 180 sec at 37°C.
Cleavage of Single-stranded DNA
To compare and map the cleavage sites of EcTOP and MtTOP, single stranded DNA substrates were generated first by PCR (Table 2) , followed by strand denaturation. Each of these substrates were radio-labeled at the 5' end by having one of the corresponding forward or reverse primers labeled with [γ-32 P]ATP in the presence of T4 polynucleotide kinase prior to the PCR. The PCR products were purified using the DNA Clean and Concentrator Kit (Zymos) and eluted in TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). Prior to the addition of topoisomerase in the cleavage assay, the DNA substrate was denatured to single strands by heating at 95°C for 5 min and rapidly cooled on ice. After incubation with the topoisomerase at 37°C for 10 min, trapping of the covalent enzyme-DNA complex and cleaved DNA was achieved by the addition of 0.1 M NaOH. After neutralization, the DNA was electrophoresed in a 6% polyacrylamide sequencing gel followed by autoradiography of the dried gel to visualize the 5'-end-labeled DNA cleavage products. DNA sequencing reaction products were generated with the same 5' end labeled primer corresponding to that of the substrate used in the cleavage assay and by following the cycle sequencing procedures according to the manufacturer's instructions (SequiTherm DNA sequencing Kit, Epicentre). The sequencing reaction products were electrophoresed next to lanes containing cleavage products to identify the cleavage sites.
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